HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hypopituitarism in five PROP1 mutation siblings: long-lasting natural course and the effects of growth hormone replacement introduction in middle adulthood.

Abstract
Twenty years after the first description of combined hypopituitarism (CPHD) caused by PROP1 mutations, the phenotype of affected subjects is still challenging for clinicians. These patients suffer from pituitary hormone deficits ranging from IGHD to panhypopituitarism. ACTH deficiency usually develops later in life. Pituitary size is variable. PROP1 mutation is the most frequent in familial congenital hypopituitarism (CH). Reports on initiation of hormonal replacement including growth hormone (GH) in adults with CH are scarce. We identified 5 adult siblings with CPHD due to PROP1 mutation (301-302delAG), aged 36-51 years (4 females), never treated for hormone deficiencies. They presented with short stature (SD from - 3.7 to - 4.7), infantile sexual characteristic, moderate abdominal obesity and low bone mineral density in 3 of them. Complete hypopituituitarism was confirmed in three siblings, while two remaining demonstrated GH, TSH, FSH and LH deficiencies. Required hormonal replacement including rhGH was initiated in all patients. After several months necessity for hydrocortisone replacement developed in all patients. After 2 years of continual replacement therapy, BMD and body composition (measured by DXA-dual X-ray absorptiometry) improved in all subjects, most prominently in two younger females and the male sibling. Besides rhGH therapy, these three patients have received sex hormones contributing to the favorable effect. The male sibling was diagnosed with brain glioblastoma two years following complete hormonal replacement. This report provides important experience regarding hormonal replacement, particularly rhGH treatment, in adults with long-term untreated CH. Beneficial effect of such therapy are widely acknowledged, yet these subjects could be susceptible to certain risks of hormonal treatment initiated in adulthood. Careful and continual clinical follow-up is thus strongly advised.
AuthorsMirjana Doknic, Vladimir Gasic, Marko Stojanovic, Sonja Pavlovic, Snezana Marinkovic, Dragana Miljic, Sandra Pekic, Emilija Manojlovic-Gacic, Dusan Damjanovic, Ivan Soldatovic, Milan Petakov
JournalPituitary (Pituitary) Vol. 23 Issue 4 Pg. 400-408 (Aug 2020) ISSN: 1573-7403 [Electronic] United States
PMID32415500 (Publication Type: Journal Article)
Chemical References
  • Gonadal Steroid Hormones
  • Homeodomain Proteins
  • Prophet of Pit-1 protein
  • Recombinant Proteins
  • Human Growth Hormone
  • Testosterone
  • Thyroxine
  • Hydrocortisone
Topics
  • Absorptiometry, Photon
  • Adult
  • Body Composition
  • Bone Density
  • Bone Diseases, Metabolic (diagnostic imaging, physiopathology)
  • Brain Neoplasms (diagnostic imaging, therapy)
  • Disease Progression
  • Female
  • Glioblastoma (diagnostic imaging, therapy)
  • Gonadal Steroid Hormones (therapeutic use)
  • Growth Disorders (physiopathology)
  • Homeodomain Proteins (genetics)
  • Hormone Replacement Therapy
  • Human Growth Hormone (therapeutic use)
  • Humans
  • Hydrocortisone (therapeutic use)
  • Hypopituitarism (drug therapy, metabolism, physiopathology)
  • Male
  • Middle Aged
  • Obesity, Abdominal (physiopathology)
  • Phenotype
  • Quality of Life
  • Recombinant Proteins
  • Sexual Infantilism (physiopathology)
  • Siblings
  • Testosterone (therapeutic use)
  • Thyroxine (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: